Press Releases

Opus Genetics Announces Upcoming Presentations on AAV-based Gene Therapy Programs for Inherited Retinal Diseases

Oral presentation on BEST1 clinical translation to be delivered during the 8th Annual Retinal Cell and Gene Therapy Innovation Summit

Two posters related to RDH12 and MERTK programs to be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023

Research Triangle Park, N.C. – April 18, 2023 – Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced leadership and collaborators will present data supporting multiple programs in its pipeline of gene therapies for inherited retinal diseases at upcoming scientific meetings.

Ash Jayagopal, Ph.D., Chief Scientific Officer of Opus, will deliver an oral presentation, titled, “Development of Endpoints for Clinical Translation of BEST1 Gene Therapy,” at the 8th Annual Retinal Cell and Gene Therapy Innovation Summit sponsored by the Foundation Fighting Blindness and the Oregon Health and Science University (OHSU) Casey Eye Institute, on Friday, April 21, 2023, at 11 a.m. CDT. The annual summit, held prior to the ARVO Annual Meeting, features presentations by leading retinal disease experts on potential gene and stem-cell therapies and how best to deliver them to patients. For more information, visit https://www.fightingblindness.org/events/innovation-summit-2023-509.

Preclinical research and advances related to retinal degenerations caused by mutations in the RDH12 and MERTK genes will be presented in poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023, being held April 23-27, 2023, in New Orleans. The ARVO Annual Meeting is the premiere gathering for eye and vision scientists to share the latest research findings and collaborate on innovative solutions.

Details of the ARVO presentations are as follows:

Title: Structural and Functional Relationships in RDH12-Associated Early-Onset Severe Inherited Retinal Degeneration
Session: Inherited Retinal Degeneration
Poster Number: B0197
Location: Exhibit Hall, New Orleans Ernest N. Morial Convention Center
Date / time: Monday, April 24, 2023, 11:30 a.m.—1:15 p.m. CDT
Presenter: Erin O’Neil, M.D., Children’s Hospital of Philadelphia

Title: Evaluation of MERTK Gene Therapy Constructs in Cell Culture Models
Session: Retinal Pigment Epithelium
Poster Number: C0099
Location: Exhibit Hall, New Orleans Ernest N. Morial Convention Center
Date / time: Tuesday, April 25, 2023, 11:45 a.m.—1:30 p.m. CDT
Presenter: Elisebeth Torretti, presenting author

For more information on the ARVO Annual Meeting, visit https://www.arvo.org/annual-meeting/.

Dr. Jayagopal has also been selected by the ARVO Annual Meeting Program Committee to organize and moderate a Special Interest Group (SIG) session, titled “Development of Endpoints for Successful Translation of Inherited Retinal Disease Therapies,” on Thursday, Sept. 28, 2023, at 6 p.m. EDT. The session will feature a global panel of experts in retinal diseases and will be held virtually. For more information, visit https://www.arvo.org/annual-meeting/program/special-interest-group-meetings/#endpoints.

About Opus Genetics

Opus Genetics is a clinical-stage gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness’ venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases. Its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. Based in Research Triangle Park, N.C., the company leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. For more information, visit www.opusgenetics.com.

Opus Media Contact:
Heather Anderson
6 Degrees
919-827-5539
[email protected]